News

02.24.22

Press Release

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022

SEATTLE, Wash and VANCOUVER, British Columbia, February 24, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its fourth quarter and year-end 2021 financial results and provide an update on the cytisinicline…

/Read More

02.03.22

Press Release

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award

SEATTLE, Wash. and VANCOUVER, British Columbia, February 3, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations….

/Read More

02.02.22

Press Release

Achieve Life Sciences Announces Participation in February Investor Conferences

SEATTLE, Wash. and VANCOUVER, British Columbia, February 2, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in the Winter Wonderland Best Ideas Virtual Investor Conference and Aegis Virtual Conference during…

/Read More

01.25.22

Press Release

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, January 25, 2022 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in…

/Read More

01.06.22

Press Release

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash and VANCOUVER, British Columbia, January 6, 2022 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will give a presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The…

/Read More